What is the clinical evidence from this study?

Study design: Other. Population: Healthy. Intervention: Hemostasis inhibitors (anti-vWf, anti-GPIb, anti-GPIIbIIIa, ATA, heparin) vs. Control (PBS or isotonic saline). Primary outcome: Platelet hemostasis time (PHT), collagen-induced thrombus formation (CITF), and clotting time (CT) (p=<0.001).

September 1, 1997Clinical Chemistry

Xylum CSA®: Automated System for Assessing Hemostasis in Simulated Vascular Flow

Q: What are the key findings of this study?

The Clot Signature Analyzer detected significant increases in platelet hemostasis time and collagen-induced thrombus formation with various inhibitors (P<0.05) and prolonged clotting time with heparin (1800s vs 1217s, P<0.001).

View Full Paper

Ask AI

Bookmark

Key result

The Clot Signature Analyzer detected significant increases in platelet hemostasis time and collagen-induced thrombus formation with various inhibitors (P<0.05) and prolonged clotting time with heparin (1800s vs 1217s, P<0.001).

Population

Blood samples from 5 to 14 apparently healthy adult donors of both sexes per test, who had refrained from…

Comparison

In vitro addition of hemostasis inhibitors or… vs Control.

Design

Preclinical

Authors

CLConan K.N. LiXybion Corporation (United States)THThomas J. HoffmannUniversity of California, San Francisco PHPei-Ying HsiehNational Astronomical Observatory of Japan

Discussion

Member takes

Implication

May support in vitro monitoring of antithrombotics with the Clot Signature Analyzer; leaves open clinical validation.

Structured PICO

Population

Blood samples from healthy adult donors were used to evaluate the Clot Signature Analyzer by mixing with various hemostasis inhibitors.

Intervention

In vitro addition of hemostasis inhibitors (anti-GPIIbIIIa 5 mg/L, anti-GPIb 5 mg/L, anti-vWf 2.5 mg/L, aurintricarboxylic acid 400 μmol/L) or unfractionated heparin (300 IU/L) to untreated whole blood.

Comparator

Control (phosphate-buffered saline or isotonic saline).

Outcome

Platelet hemostasis time (PHT), collagen-induced thrombus formation (CITF), and clotting time (CT) measured by the Clot Signature Analyzer (CSA).surrogate

Main Result

Absolute Event Rate: 1800% vs 1217%

p-value: p=<0.001

The automated Clot Signature Analyzer can effectively detect abnormal hemostasis and coagulation in untreated whole blood under simulated physiological flow conditions.

Cite This Study

Li et al. (1997) studied Healthy. Hemostasis inhibitors (anti-vWf, anti-GPIb, anti-GPIIbIIIa, ATA, heparin) vs. Control (PBS or isotonic saline) was evaluated on Platelet hemostasis time (PHT), collagen-induced thrombus formation (CITF), and clotting time (CT) (p=<0.001). The Clot Signature Analyzer detected significant increases in platelet hemostasis time and collagen-induced thrombus formation with various inhibitors (P<0.05) and prolonged clotting time with heparin (1800s vs 1217s, P<0.001).

synapsesocial.com/papers/6a6ac16a547974b2dbf41f06 https://doi.org/10.1093/clinchem/43.9.1788

View Full Paper

Ask AI

Bookmark

September 1, 1997Clinical Chemistry

Xylum CSA®: Automated System for Assessing Hemostasis in Simulated Vascular Flow

View Full Paper

Ask AI

Bookmark

Key result

Population

Blood samples from 5 to 14 apparently healthy adult donors of both sexes per test, who had refrained from…

Comparison

In vitro addition of hemostasis inhibitors or… vs Control.

Design

Preclinical

Authors

CLConan K.N. LiXybion Corporation (United States)THThomas J. HoffmannUniversity of California, San Francisco PHPei-Ying HsiehNational Astronomical Observatory of Japan

Discussion

Member takes

Implication

May support in vitro monitoring of antithrombotics with the Clot Signature Analyzer; leaves open clinical validation.

Structured PICO

Population

Blood samples from healthy adult donors were used to evaluate the Clot Signature Analyzer by mixing with various hemostasis inhibitors.

Intervention

Comparator

Control (phosphate-buffered saline or isotonic saline).

Outcome

Platelet hemostasis time (PHT), collagen-induced thrombus formation (CITF), and clotting time (CT) measured by the Clot Signature Analyzer (CSA).surrogate

Main Result

Absolute Event Rate: 1800% vs 1217%

p-value: p=<0.001

The automated Clot Signature Analyzer can effectively detect abnormal hemostasis and coagulation in untreated whole blood under simulated physiological flow conditions.

Cite This Study

synapsesocial.com/papers/6a6ac16a547974b2dbf41f06 https://doi.org/10.1093/clinchem/43.9.1788

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark